94 related articles for article (PubMed ID: 9051134)
1. [Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
Kuga T; Kohda K; Matsumoto S; Nakazawa O; Ezoe A; Nobuoka A; Mochizuki C; Niitsu Y; Watanabe N
Gan To Kagaku Ryoho; 1997 Feb; 24(3):315-21. PubMed ID: 9051134
[TBL] [Abstract][Full Text] [Related]
2. [Late phase II study with 21-consecutive-day oral administration of etoposide for malignant lymphoma].
Yoshida T; Takagi T; Shimoyama M; Mikuni C; Suzuki K; Egami K; Furusawa S; Nomura T; Mori M; Sugimoto T
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2793-801. PubMed ID: 7993116
[TBL] [Abstract][Full Text] [Related]
3. [Oral administration of etoposide therapy in refractory malignant lymphoma and adult T cell lymphoma].
Honda J; Osabe S; Yosida K; Nakamura E; Tanaka K; Natori H; Oizumi K; Sakamoto A; Imamura Y; Naito K
Gan To Kagaku Ryoho; 1991 Apr; 18(4):653-6. PubMed ID: 2012405
[No Abstract] [Full Text] [Related]
4. [EPOCH therapy for relapsed/refractory lymphoid malignancies].
Dobashi N; Usui N; Kobayashi T; Yamazaki H; Asai O; Yano S; Kato A; Watanabe H; Nagamine M; Katori M; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Apr; 39(4):267-72. PubMed ID: 9597893
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
6. [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders].
Tagawa S; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan No Rinsho; 1987 Jan; 33(1):1-7. PubMed ID: 3469424
[TBL] [Abstract][Full Text] [Related]
7. [Successful chronic daily administration of oral etoposide for a case of adult T cell leukemia].
Matsuoka H; Toyama T; Horinouchi M; Maeda K; Suzuki M; Kubuki Y; Komura K; Ishikawa T; Uno H; Tsubouchi H
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1387-90. PubMed ID: 8346938
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of adult T-cell leukemia . lymphoma (ATL) with long-term remission by chronic daily administration of low-dose etoposide].
Ezoe A; Kohda K; Hirayama Y; Nobuoka A; Matsumoto S; Nakazawa O; Takahashi H; Muramatsu H; Matsunaga T; Watanabe N
Gan To Kagaku Ryoho; 1995 Mar; 22(4):547-52. PubMed ID: 7887647
[TBL] [Abstract][Full Text] [Related]
10. [Oral administration of low-dose etoposide for maintenance chemotherapy in adult T cell leukemia patients].
Utsunomiya A; Takatsuka Y; Takeshita T; Makino T; Ishitsuka K; Shimotakahara S; Ohno N; Kuwazuru Y; Uozumi K; Saito T
Gan To Kagaku Ryoho; 1994 May; 21(6):839-44. PubMed ID: 8185342
[TBL] [Abstract][Full Text] [Related]
11. [Adult T cell leukemia/lymphoma effectively treated with chronic oral etoposide].
Yamane T; Ohta K; Nakao Y; Yasui Y; Shindo K; Tanaka K; Hasuike T; Hirai M; Takekawa K; Hirai N
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1853-6. PubMed ID: 8379679
[TBL] [Abstract][Full Text] [Related]
12. [A case of gastric malignant lymphoma markedly responding to chronic daily and oral administration of low-dose etoposide].
Moriya A; Ikeda A; Yokoyama N; Yokoyama T; Abe Y; Miyamoto K
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2229-33. PubMed ID: 8239691
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
17. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
18. [Waldenström's macroglobulinemia effectively treated with chronic daily oral administration of low-dose etoposide].
Itoh K; Shimada T; Horibe T; Kawai N; Sakata T; Fukuda M; Murohashi I; Bessho M; Takeuchi H; Hirashima K
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2131-4. PubMed ID: 9838919
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
20. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
